The presence of host cell proteins (HCPs) as process-related impurities in monoclonal antibody (mAb) therapeutics presents risks, including immunogenicity, product instability, and reduced therapeutic efficacy. Therefore, HCP levels are seen as a critical qual... ...

请注册登录后继续浏览